Sanuwave Health (SNWV) Projected to Post Earnings on Tuesday

Sanuwave Health (NASDAQ:SNWV) will likely be posting its Q4 2025 resultson Tuesday, April 7th. Analysts expect Sanuwave Health to post earnings of $0.17 per share and revenue of $13.25 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:30 AM ET.

Sanuwave Health (NASDAQ:SNWV) last released its earnings results on Thursday, March 26th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.14). Sanuwave Health had a negative return on equity of 141.56% and a net margin of 26.64%.The company had revenue of $13.09 million during the quarter, compared to the consensus estimate of $13.23 million.

Sanuwave Health Price Performance

Shares of NASDAQ:SNWV opened at $17.39 on Tuesday. The company has a market capitalization of $149.38 million, a PE ratio of -108.68 and a beta of 1.32. The business has a fifty day moving average price of $23.83 and a 200-day moving average price of $29.20. Sanuwave Health has a 1-year low of $16.69 and a 1-year high of $46.58. The company has a debt-to-equity ratio of 10.08, a current ratio of 1.38 and a quick ratio of 1.05.

Institutional Trading of Sanuwave Health

A number of hedge funds have recently bought and sold shares of SNWV. Legal & General Group Plc purchased a new position in Sanuwave Health in the second quarter worth about $26,000. Charles Schwab Investment Management Inc. increased its position in shares of Sanuwave Health by 4.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,398 shares of the company’s stock valued at $728,000 after purchasing an additional 1,135 shares during the last quarter. Barclays PLC lifted its stake in shares of Sanuwave Health by 12.7% in the 4th quarter. Barclays PLC now owns 11,610 shares of the company’s stock worth $346,000 after purchasing an additional 1,306 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Sanuwave Health in the second quarter worth approximately $46,000. Finally, Russell Investments Group Ltd. bought a new stake in Sanuwave Health during the third quarter valued at approximately $67,000. Hedge funds and other institutional investors own 42.53% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday. Wall Street Zen cut Sanuwave Health from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Roth Mkm reiterated a “buy” rating and set a $47.00 target price (down from $53.00) on shares of Sanuwave Health in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Sanuwave Health has a consensus rating of “Buy” and an average target price of $51.00.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.